CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.63 Billion KRW | -182.32% |
| 2022 | 2.28 Billion KRW | -55.84% |
| 2021 | 5.56 Billion KRW | -61.96% |
| 2020 | 19.86 Billion KRW | -29.16% |
| 2019 | 25.56 Billion KRW | 43.54% |
| 2018 | 15.96 Billion KRW | 5.55% |
| 2017 | 18.86 Billion KRW | -17.68% |
| 2016 | 21.26 Billion KRW | 6.88% |
| 2015 | 19.18 Billion KRW | 102.99% |
| 2014 | 9.81 Billion KRW | -31.24% |
| 2013 | 14.33 Billion KRW | -31.53% |
| 2012 | 20.9 Billion KRW | -12.9% |
| 2011 | 23.46 Billion KRW | -10.58% |
| 2010 | 26.9 Billion KRW | 14.54% |
| 2009 | 24.02 Billion KRW | 48.22% |
| 2008 | 16.63 Billion KRW | 429.65% |
| 2007 | 2.79 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 3.18 Billion KRW | 771.26% |
| 2024 Q2 | 4.98 Billion KRW | 13.14% |
| 2024 Q3 | 2.57 Billion KRW | -73.86% |
| 2023 Q2 | -1.3 Billion KRW | -284.67% |
| 2023 Q4 | -604.45 Million KRW | -123.99% |
| 2023 FY | - KRW | -182.32% |
| 2023 Q1 | 709.16 Million KRW | 114.71% |
| 2023 Q3 | 2.51 Billion KRW | 292.38% |
| 2022 Q3 | 3.36 Billion KRW | 681.01% |
| 2022 Q2 | 431.1 Million KRW | -89.71% |
| 2022 Q1 | 4.19 Billion KRW | 608.18% |
| 2022 FY | - KRW | -55.84% |
| 2022 Q4 | -4.82 Billion KRW | -243.19% |
| 2021 Q2 | -1.22 Billion KRW | 16.25% |
| 2021 Q1 | -1.46 Billion KRW | 38.51% |
| 2021 Q3 | 1.18 Billion KRW | 197.03% |
| 2021 Q4 | 591.85 Million KRW | -50.16% |
| 2021 FY | - KRW | -61.96% |
| 2020 Q1 | 4.57 Billion KRW | 20.82% |
| 2020 Q3 | 925.63 Million KRW | -73.52% |
| 2020 Q4 | -2.37 Billion KRW | -356.71% |
| 2020 FY | - KRW | -29.16% |
| 2020 Q2 | 3.49 Billion KRW | -23.66% |
| 2019 Q1 | 5.52 Billion KRW | 25.95% |
| 2019 Q3 | 5.32 Billion KRW | 15.39% |
| 2019 Q4 | 3.78 Billion KRW | -28.83% |
| 2019 FY | - KRW | 43.54% |
| 2019 Q2 | 4.61 Billion KRW | -16.49% |
| 2018 Q2 | 4.11 Billion KRW | -15.28% |
| 2018 Q3 | 5.17 Billion KRW | 25.75% |
| 2018 FY | - KRW | 5.55% |
| 2018 Q1 | 4.86 Billion KRW | 56.38% |
| 2018 Q4 | 4.38 Billion KRW | -15.29% |
| 2017 Q1 | 4.95 Billion KRW | -0.35% |
| 2017 FY | - KRW | -17.68% |
| 2017 Q4 | 3.1 Billion KRW | -47.16% |
| 2017 Q3 | 5.88 Billion KRW | 12.75% |
| 2017 Q2 | 5.21 Billion KRW | 5.21% |
| 2016 FY | - KRW | 6.88% |
| 2016 Q4 | 4.97 Billion KRW | 32.7% |
| 2016 Q3 | 3.75 Billion KRW | -38.51% |
| 2016 Q2 | 6.09 Billion KRW | -5.3% |
| 2016 Q1 | 6.43 Billion KRW | 11.8% |
| 2015 FY | - KRW | 102.99% |
| 2015 Q2 | 3.91 Billion KRW | 5.55% |
| 2015 Q3 | 6.59 Billion KRW | 68.44% |
| 2015 Q1 | 3.7 Billion KRW | 46.75% |
| 2015 Q4 | 5.75 Billion KRW | -12.6% |
| 2014 Q3 | 2.52 Billion KRW | 35.54% |
| 2014 Q2 | 1.86 Billion KRW | -36.35% |
| 2014 Q1 | 2.92 Billion KRW | 5.29% |
| 2014 Q4 | 2.52 Billion KRW | 0.09% |
| 2014 FY | - KRW | -31.24% |
| 2013 FY | - KRW | -31.53% |
| 2013 Q2 | 3.85 Billion KRW | -3.31% |
| 2013 Q3 | 3.68 Billion KRW | -4.6% |
| 2013 Q1 | 3.98 Billion KRW | 3.67% |
| 2013 Q4 | 2.77 Billion KRW | -24.5% |
| 2012 FY | - KRW | -12.9% |
| 2012 Q4 | 3.84 Billion KRW | -37.59% |
| 2012 Q3 | 6.16 Billion KRW | 2.19% |
| 2012 Q2 | 6.03 Billion KRW | 24.6% |
| 2012 Q1 | 4.84 Billion KRW | -32.83% |
| 2011 Q1 | 6.37 Billion KRW | -9.2% |
| 2011 FY | - KRW | -10.58% |
| 2011 Q4 | 7.21 Billion KRW | 41.28% |
| 2011 Q3 | 5.1 Billion KRW | 4.77% |
| 2011 Q2 | 4.87 Billion KRW | -23.56% |
| 2010 Q3 | 8.3 Billion KRW | 32.05% |
| 2010 FY | - KRW | 14.54% |
| 2010 Q2 | 6.28 Billion KRW | 20.63% |
| 2010 Q1 | 5.21 Billion KRW | 83.56% |
| 2010 Q4 | 7.01 Billion KRW | -15.48% |
| 2009 Q4 | 2.84 Billion KRW | -65.25% |
| 2009 FY | - KRW | 48.22% |
| 2009 Q2 | 4.73 Billion KRW | -38.19% |
| 2009 Q1 | 7.66 Billion KRW | 51.87% |
| 2009 Q3 | 8.17 Billion KRW | 72.46% |
| 2008 Q3 | 5.98 Billion KRW | 169.24% |
| 2008 Q4 | 5.04 Billion KRW | -15.67% |
| 2008 Q1 | 2.54 Billion KRW | 539.56% |
| 2008 FY | - KRW | 429.65% |
| 2008 Q2 | 2.22 Billion KRW | -12.5% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 1.53 Billion KRW | -10.44% |
| 2007 Q1 | 310.87 Million KRW | 0.0% |
| 2007 Q2 | 1.71 Billion KRW | 451.57% |
| 2007 Q4 | -578.13 Million KRW | -137.65% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 133.56% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 101.153% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 97.454% |
| HANDOK Inc. | 35.06 Billion KRW | 104.65% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | -57.291% |
| Yuhan Corporation | 127.43 Billion KRW | 101.279% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 104.345% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 92.482% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 100.504% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 132.672% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 110.785% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | 147.66% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 136.021% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 104.595% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 133.56% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 91.173% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 124.873% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 96.692% |
| JW Holdings Corporation | 187.88 Billion KRW | 100.868% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 96.817% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 100.575% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 101.827% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 95.601% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 112.343% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 113.785% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 108.74% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 133.56% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 102.966% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 100.989% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 101.827% |
| Yuhan Corporation | 127.43 Billion KRW | 101.279% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 104.87% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 121.313% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 102.117% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 101.827% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 104.451% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 102.304% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 103.274% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 105.007% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 104.429% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 95.601% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 102.618% |
| Boryung Corporation | 114.28 Billion KRW | 101.427% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 94.666% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 110.785% |
| JW Lifescience Corporation | 50.82 Billion KRW | 103.208% |